Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus

S. Ascioglu; J. H. Rex; B. De Pauw; J. E. Bennett; J. Bille; F. Crokaert; D. W. Denning; J. P. Donnelly; J. E. Edwards; Z. Erjavec; D. Fiere; O. Lortholary; J. Maertens; J. F. Meis; T. F. Patterson; J. Ritter; D. Selleslag; P. M. Shah; D. A. Stevens; T. J. Walsh

doi:10.1086/323335

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus

S. Ascioglu, J. H. Rex, B. De Pauw, J. E. Bennett, J. Bille, F. Crokaert, D. W. Denning, J. P. Donnelly, J. E. Edwards, Z. Erjavec, D. Fiere, O. Lortholary, J. Maertens, J. F. Meis, T. F. Patterson, J. Ritter, D. Selleslag, P. M. Shah, D. A. Stevens, T. J. Walsh

Research output: Contribution to journal › Article › peer-review

2075 Scopus citations

Abstract

During the past several decades, there has been a steady increase in the frequency of opportunistic invasive fungal infections (IFIs) in immunocompromised patients. However, there is substantial controversy concerning optimal diagnostic criteria for these IFIs. Therefore, members of the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group formed a consensus committee to develop standard definitions for IFIs for clinical research. On the basis of a review of literature and an international consensus, a set of research-oriented definitions for the IFIs most often seen and studied in immunocompromised patients with cancer is proposed. Three levels of probability are proposed: "proven," "probable," and "possible." The definitions are intended for use in the context of clinical and/or epidemiological research, not for clinical decision making.

Original language	English (US)
Pages (from-to)	7-14
Number of pages	8
Journal	Clinical Infectious Diseases
Volume	34
Issue number	1
DOIs	https://doi.org/10.1086/323335
State	Published - Jan 1 2002
Externally published	Yes

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1086/323335

Cite this

Ascioglu, S., Rex, J. H., De Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., Fiere, D., Lortholary, O., Maertens, J., Meis, J. F., Patterson, T. F., Ritter, J., Selleslag, D., Shah, P. M., Stevens, D. A., & Walsh, T. J. (2002). Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clinical Infectious Diseases, 34(1), 7-14. https://doi.org/10.1086/323335

Ascioglu, S, Rex, JH, De Pauw, B, Bennett, JE, Bille, J, Crokaert, F, Denning, DW, Donnelly, JP, Edwards, JE, Erjavec, Z, Fiere, D, Lortholary, O, Maertens, J, Meis, JF, Patterson, TF, Ritter, J, Selleslag, D, Shah, PM, Stevens, DA & Walsh, TJ 2002, 'Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus', Clinical Infectious Diseases, vol. 34, no. 1, pp. 7-14. https://doi.org/10.1086/323335

@article{af1cb1cd778f4511a607e78cca74243e,

title = "Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus",

abstract = "During the past several decades, there has been a steady increase in the frequency of opportunistic invasive fungal infections (IFIs) in immunocompromised patients. However, there is substantial controversy concerning optimal diagnostic criteria for these IFIs. Therefore, members of the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group formed a consensus committee to develop standard definitions for IFIs for clinical research. On the basis of a review of literature and an international consensus, a set of research-oriented definitions for the IFIs most often seen and studied in immunocompromised patients with cancer is proposed. Three levels of probability are proposed: {"}proven,{"} {"}probable,{"} and {"}possible.{"} The definitions are intended for use in the context of clinical and/or epidemiological research, not for clinical decision making.",

author = "S. Ascioglu and Rex, {J. H.} and {De Pauw}, B. and Bennett, {J. E.} and J. Bille and F. Crokaert and Denning, {D. W.} and Donnelly, {J. P.} and Edwards, {J. E.} and Z. Erjavec and D. Fiere and O. Lortholary and J. Maertens and Meis, {J. F.} and Patterson, {T. F.} and J. Ritter and D. Selleslag and Shah, {P. M.} and Stevens, {D. A.} and Walsh, {T. J.}",

note = "Funding Information: Financial support: Unrestricted educational grant from Pfizer (to S.A.); European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group (to S.A.); Aronex, Janssen Research Foundation, Liposome Company, NeXstar-Gilead, and Pfizer.",

year = "2002",

month = jan,

day = "1",

doi = "10.1086/323335",

language = "English (US)",

volume = "34",

pages = "7--14",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants

T2 - An international consensus

AU - Ascioglu, S.

AU - Rex, J. H.

AU - De Pauw, B.

AU - Bennett, J. E.

AU - Bille, J.

AU - Crokaert, F.

AU - Denning, D. W.

AU - Donnelly, J. P.

AU - Edwards, J. E.

AU - Erjavec, Z.

AU - Fiere, D.

AU - Lortholary, O.

AU - Maertens, J.

AU - Meis, J. F.

AU - Patterson, T. F.

AU - Ritter, J.

AU - Selleslag, D.

AU - Shah, P. M.

AU - Stevens, D. A.

AU - Walsh, T. J.

N1 - Funding Information: Financial support: Unrestricted educational grant from Pfizer (to S.A.); European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group (to S.A.); Aronex, Janssen Research Foundation, Liposome Company, NeXstar-Gilead, and Pfizer.

PY - 2002/1/1

Y1 - 2002/1/1

N2 - During the past several decades, there has been a steady increase in the frequency of opportunistic invasive fungal infections (IFIs) in immunocompromised patients. However, there is substantial controversy concerning optimal diagnostic criteria for these IFIs. Therefore, members of the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group formed a consensus committee to develop standard definitions for IFIs for clinical research. On the basis of a review of literature and an international consensus, a set of research-oriented definitions for the IFIs most often seen and studied in immunocompromised patients with cancer is proposed. Three levels of probability are proposed: "proven," "probable," and "possible." The definitions are intended for use in the context of clinical and/or epidemiological research, not for clinical decision making.

AB - During the past several decades, there has been a steady increase in the frequency of opportunistic invasive fungal infections (IFIs) in immunocompromised patients. However, there is substantial controversy concerning optimal diagnostic criteria for these IFIs. Therefore, members of the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group formed a consensus committee to develop standard definitions for IFIs for clinical research. On the basis of a review of literature and an international consensus, a set of research-oriented definitions for the IFIs most often seen and studied in immunocompromised patients with cancer is proposed. Three levels of probability are proposed: "proven," "probable," and "possible." The definitions are intended for use in the context of clinical and/or epidemiological research, not for clinical decision making.

UR - http://www.scopus.com/inward/record.url?scp=0036133373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036133373&partnerID=8YFLogxK

U2 - 10.1086/323335

DO - 10.1086/323335

M3 - Article

C2 - 11731939

AN - SCOPUS:0036133373

SN - 1058-4838

VL - 34

SP - 7

EP - 14

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 1

ER -

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this